Furthermore, 22% of all recruited cRCC patients were carriers of combined GSTM1-null, GSTT1-active, GSTA1 low-activity and GSTP1-variant genotype, which might be considered as “risk-carrying genotype combination”, since these individuals had 9.32-fold increased susceptibility to cRCC. This evidence concerns the gene GSTM1 and chromophobe renal cell carcinoma.